These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 29630523

  • 1. MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia.
    Krejcik Z, Belickova M, Hrustincova A, Votavova H, Jonasova A, Cermak J, Dyr JE, Merkerova MD.
    Cancer Biomark; 2018; 22(1):101-110. PubMed ID: 29630523
    [Abstract] [Full Text] [Related]

  • 2. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
    Mongiorgi S, De Stefano A, Ratti S, Indio V, Astolfi A, Casalin I, Pellagatti A, Paolini S, Parisi S, Cavo M, Pession A, McCubrey JA, Suh PG, Manzoli L, Boultwood J, Finelli C, Cocco L, Follo MY.
    Clin Epigenetics; 2023 Feb 20; 15(1):27. PubMed ID: 36803590
    [Abstract] [Full Text] [Related]

  • 3. Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.
    Monika Belickova M, Merkerova MD, Votavova H, Valka J, Vesela J, Pejsova B, Hajkova H, Klema J, Cermak J, Jonasova A.
    Int J Hematol; 2016 Nov 20; 104(5):566-573. PubMed ID: 27416819
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C, Westers TM, van der Helm LH, Eeltink C, Huls G, Witte BI, Buchi F, Santini V, Ossenkoppele GJ, van de Loosdrecht AA.
    Cytometry B Clin Cytom; 2014 May 20; 86(3):207-15. PubMed ID: 24474614
    [Abstract] [Full Text] [Related]

  • 7. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
    Mpakou V, Spathis A, Bouchla A, Tsakiraki Z, Kontsioti F, Papageorgiou S, Bazani E, Gkontopoulos K, Thomopoulos T, Glezou I, Galanopoulos A, Symeonidis A, Diamantopoulos PT, Viniou NA, Kontandreopoulou CN, Zafeiropoulou K, Kotsianidis I, Lamprianidou E, Foukas P, Mpamias A, Pappa V.
    Hematol Oncol; 2021 Apr 20; 39(2):231-242. PubMed ID: 33332639
    [Abstract] [Full Text] [Related]

  • 8. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
    Woo J, Howard NP, Storer BE, Fang M, Yeung CC, Scott BL, Deeg HJ.
    Haematologica; 2017 Jun 20; 102(6):e216-e218. PubMed ID: 28209655
    [No Abstract] [Full Text] [Related]

  • 9. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
    Fozza C, Corda G, Barraqueddu F, Virdis P, Contini S, Galleu A, Isoni A, Dore F, Angelucci E, Longinotti M.
    Leuk Res; 2015 Sep 20; 39(9):957-63. PubMed ID: 26209197
    [Abstract] [Full Text] [Related]

  • 10. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
    Cabezón M, Malinverni R, Bargay J, Xicoy B, Marcé S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jiménez MJ, Hoyos M, Valcárcel D, Escoda L, Vall-Llovera F, Garcia A, Font LL, Rámila E, Buschbeck M, Zamora L, CETLAM group.
    Clin Epigenetics; 2021 Jan 14; 13(1):9. PubMed ID: 33446256
    [Abstract] [Full Text] [Related]

  • 11. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
    Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L.
    Leuk Res; 2017 Dec 14; 63():72-77. PubMed ID: 29112938
    [Abstract] [Full Text] [Related]

  • 12. Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse.
    Ueda M, El-Jurdi N, Cooper B, Caimi P, Baer L, Kolk M, Brister L, Wald DN, Otegbeye F, Lazarus HM, Sandmaier BM, William B, Saunthararajah Y, Woost P, Jacobberger JW, de Lima M.
    Biol Blood Marrow Transplant; 2019 Jun 14; 25(6):1122-1127. PubMed ID: 30599207
    [Abstract] [Full Text] [Related]

  • 13. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
    Müller-Thomas C, Rudelius M, Rondak IC, Haferlach T, Schanz J, Huberle C, Schmidt B, Blaser R, Kremer M, Peschel C, Germing U, Platzbecker U, Götze K.
    Haematologica; 2014 Oct 14; 99(10):e179-81. PubMed ID: 24972774
    [No Abstract] [Full Text] [Related]

  • 14. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
    Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, Gore SD, Tallman MS.
    J Clin Oncol; 2014 Apr 20; 32(12):1242-8. PubMed ID: 24663049
    [Abstract] [Full Text] [Related]

  • 15. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
    Radujkovic A, Schnitzler P, Ho AD, Dreger P, Luft T.
    Clin Nutr; 2017 Apr 20; 36(2):542-551. PubMed ID: 26899917
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P.
    Leuk Res; 2014 Jul 20; 38(7):751-5. PubMed ID: 24836762
    [Abstract] [Full Text] [Related]

  • 17. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
    Merkel D, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Ofran Y.
    Am J Hematol; 2013 Feb 20; 88(2):130-4. PubMed ID: 23345248
    [Abstract] [Full Text] [Related]

  • 18. [Azacitidine treatment for acute myeloid leukemia with myelodysplasia-related changes during peritoneal dialysis].
    Omatsu T, Udaka K, Shibata H, Sekimoto E, Ozaki S.
    Rinsho Ketsueki; 2017 Feb 20; 58(12):2369-2374. PubMed ID: 29332868
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
    García-Delgado R, de Miguel D, Bailén A, González JR, Bargay J, Falantes JF, Andreu R, Ramos F, Tormo M, Brunet S, Figueredo A, Casaño J, Medina A, Badiella L, Jurado AF, Sanz G.
    Leuk Res; 2014 Jul 20; 38(7):744-50. PubMed ID: 24795069
    [Abstract] [Full Text] [Related]

  • 20. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.
    Health Technol Assess; 2010 May 20; 14 Suppl 1():69-74. PubMed ID: 20507806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.